Halozyme Therapeutics, Inc. $HALO Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 96.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 126,243 shares of the biopharmaceutical company’s stock after selling 3,589,937 shares during the quarter. Gabelli Funds LLC owned 0.10% of Halozyme Therapeutics worth $6,567,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of HALO. EverSource Wealth Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the last quarter. Brown Advisory Inc. lifted its holdings in Halozyme Therapeutics by 0.6% in the second quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after acquiring an additional 224 shares during the period. VELA Investment Management LLC boosted its position in Halozyme Therapeutics by 2.0% in the 2nd quarter. VELA Investment Management LLC now owns 12,989 shares of the biopharmaceutical company’s stock worth $676,000 after purchasing an additional 260 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its position in Halozyme Therapeutics by 2.6% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 14,429 shares of the biopharmaceutical company’s stock worth $921,000 after purchasing an additional 367 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its stake in shares of Halozyme Therapeutics by 0.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 42,473 shares of the biopharmaceutical company’s stock worth $2,209,000 after purchasing an additional 384 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on HALO shares. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus target price of $75.10.

Halozyme Therapeutics Trading Down 1.6%

Shares of Halozyme Therapeutics stock opened at $61.87 on Wednesday. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics, Inc. has a twelve month low of $46.26 and a twelve month high of $79.50. The firm has a market capitalization of $7.28 billion, a PE ratio of 13.03, a P/E/G ratio of 0.34 and a beta of 0.95. The firm’s 50-day moving average price is $67.74 and its 200 day moving average price is $64.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.27 earnings per share. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00. Following the completion of the transaction, the director directly owned 42,952 shares in the company, valued at approximately $2,941,352.96. This represents a 4.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 83,625 shares of company stock worth $5,932,527. Corporate insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.